A practical reference on regulatory status: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-05. Anything still debated is marked as such rather than presented as settled.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
There are relatively simple tests for radon gas. In some countries these tests are methodically done in areas of known systematic hazards. Radon detection devices are commercially available. Digital radon detectors provide ongoing measurements giving both daily, weekly, short-term and long-term average readouts via a digital display. Short-term radon test devices used for initial screening purposes are inexpensive, in some cases free. There are important protocols for taking short-term radon tests and it is imperative that they be strictly followed. The kit includes a collector that the user hangs in the lowest habitable floor of the house for two to seven days. The user then sends the collector to a laboratory for analysis. Long term kits, taking collections for up to one year or more, are also available. An open-land test kit can test radon emissions from the land before construction begins. Radon concentrations can vary daily, and accurate radon exposure estimates require long-term average radon measurements in the spaces where an individual spends a significant amount of time. Radon levels fluctuate naturally, due to factors like transient weather conditions, so an initial test might not be an accurate assessment of a home's average radon level. Radon levels are at a maximum during the coolest part of the day when pressure differentials are greatest. Therefore, a high result (over 4 pCi/L) justifies repeating the test before undertaking more expensive abatement projects. Measurements between 4 and 10 pCi/L warrant a long-term radon test.
Plutonium-241 (241Pu, Pu-241) is an isotope of plutonium formed when plutonium-240 captures a neutron. Like some other plutonium isotopes (especially 239Pu), 241Pu is fissile, with a neutron absorption cross section about one-third greater than that of 239Pu, and a similar probability of fissioning on neutron absorption, around 73%. In the non-fission case, neutron capture produces plutonium-242. In general, isotopes with an odd number of neutrons are both more likely to absorb a neutron and more likely to undergo fission on neutron absorption than isotopes with an even number of neutrons.
(2026) study the visibility of fallow deer in broad-leaved woodland environment, and interpret purported hunting lesions on fossil bones of fallow deer as placed in areas that would be visible to Palaeolithic hunters in such environments. Evidence indicating that Aurignacian artifacts from cave sites in southwestern Germany were adorned with geometric sign sequences of comparable complexity to that of early proto-cuneiform is presented by Bentz & Dutkiewicz (2026). Conard, Janas & Zeidi (2026) report the discovery of two Aurignacian bird figurines made from mammoth ivory in the Hohle Fels cave (Germany). Isle de Beauchaine et al. (2026) study the morphology of teeth in the Aurignacian mandible Les Rois 2 from the Les Rois cave (Charente, France), interpreted as consistent with assignment of the specimen to an anatomically modern human. Röding et al. (2026) study the morphology of the Late Pleistocene frontal bone from Hahnöfersand (Germany) described by Bräuer (1980), interpret it as falling within the variability of Holocene Homo sapiens, and find no evidence of a morphology intermediate between those of Neanderthals and modern humans. Bossoms Mesa et al. (2026) report evidence of preservation of human DNA in pigment samples collected in and around Paleolithic rock art, including preservation of DNA resulting from deposition through direct human contact in the Escoural Cave (Portugal).
=== Mental processes === The twelve nidanas have also been interpreted within various Buddhist traditions as explaining the arising of psychological or phenomenological processes in the present moment or across a series of moments.
=== Perioperative medicine === Clonidine is sometimes used in perioperative medicine as an adjunctive therapy during the perioperative period, where it is administered alongside other analgesics to provide sedation and pain-control. Whilst clonidine itself has limited clinical utility as a monotherapy for postoperative pain, its combination with opioid medications may allow adequate pain relief to be achieved at lower opioid doses, which may reduce the frequency and severity of opioid-related adverse effects. Compared with other sedative and opioid medications used perioperatively, clonidine does not produce respiratory depression or anterograde amnesia. Moreover, its hemodynamic-stabilising effects and ability to reduce postoperative shivering are considered particularly useful in patients at high risk of myocardial ischaemia. Clonidine also has anxiolytic properties that may help reduce preoperative anxiety. In perioperative settings, clonidine may be orally ingested during the preoperative stage or administered intravenously or intramuscularly immediately before, during or shortly after surgery. Clonidine can also be administered via epidural or intrathecal catheters as an adjuvant to local anesthetics to enhance perioperative and postoperative neuraxial blockade. Clonidine's analgesic effects are attributed in part to activation of α2 adrenoreceptors within the dorsal horn of the spinal cord, which inhibits the release of pronociceptive neurotransmitters from primary afferent terminals and hyperpolarizes nociceptive interneurons.
Sources: en.wikipedia.org
the route of entry of the pathogen and the access to host regions that it gains the intrinsic virulence of the particular organism the quantity or load of the initial inoculant the immune status of the host being colonized As an example, several staphylococcal species remain harmless on the skin, but, when present in a normally sterile space, such as in the capsule of a joint or the peritoneum, multiply without resistance and cause harm. An interesting fact that gas chromatography–mass spectrometry, 16S ribosomal RNA analysis, omics, and other advanced technologies have made more apparent to humans in recent decades is that microbial colonization is very common even in environments that humans think of as being nearly sterile. Because it is normal to have bacterial colonization, it is difficult to know which chronic wounds can be classified as infected and how much risk of progression exists. Despite the huge number of wounds seen in clinical practice, there are limited quality data for evaluated symptoms and signs. A review of chronic wounds in the Journal of the American Medical Association's "Rational Clinical Examination Series" quantified the importance of increased pain as an indicator of infection. The review showed that the most useful finding was an increase in the level of pain (likelihood ratio range, 11–20), which makes infection much more likely; the absence of pain (likelihood ratio range, 0.64–0.88) does not rule out infection.
==== Health claims ==== The Japanese Ministry of Health, Labor, and Welfare (MHLW) set up the 'Foods for Specified Health Uses' (特定保健用食品; FOSHU) regulatory system in 1991 to individually approve the statements made on food labels concerning the effects of foods on the human body. The regulatory range of FOSHU was later broadened to allow for the certification of capsules and tablets. In 2001, MHLW enacted a new regulatory system, 'Foods with Health Claims' (保健機能食品; FHC), which consists of the existing FOSHU system and the newly established 'Foods with Nutrient Function Claims' (栄養機能表示食品; FNFC), under which claims were approved for any product containing a specified amount per serving of 12 vitamins, including vitamin B6, and two minerals. To make a health claim based on a food's vitamin B6 content, the amount per serving must be in the range of 0.3–25 mg. The allowed claim is: "Vitamin B6 is a nutrient that helps produce energy from protein and helps maintain healthy skin and mucous membranes." In 2010, the European Food Safety Authority (EFSA) published a review of proposed health claims for vitamin B6, disallowing claims for bone, teeth, hair skin and nails, and allowing claims that the vitamin provided for normal homocysteine metabolism, normal energy-yielding metabolism, normal psychological function, reduced tiredness and fatigue, and provided for normal cysteine synthesis. The US Food and Drug Administration (FDA) has several processes for permitting health claims on food and dietary supplement labels.
On October 17, faced with the PAVN's demonstrated ability to fight a conventional battle, the French command decided to abandon Lạng Sơn before it could come under attack, leaving behind considerable amounts of military supplies. The Viet-Minh now controlled most of the northern half of Tonkin.
=== Protein modification === A classic way to crystalize is by adding a small amount of protease to the droplet, as digestion may yield a more crystallizable fragment by removing unstructured regions. Chemical modification can be used to improve crystallization. The most commonly used is reductive methylation, which changes surface lysines in a way that usually reduces entropy.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.